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Abstract
Abacavir is a nucleoside reverse transcriptase inhibitor used as part of combination antire-
troviral therapy in HIV-1-infected patients. Because this drug can cause a hypersensitivity
reaction that is correlated with the presence of the HLA-B*57:01allotype, screening for the
presence of HLA-B*57:01 is recommended before abacavir initiation. Different genetic as-
says have been developed for HLA-B*57:01 screening, each with specific sensitivity, turn-
around time and assay costs. Here, a new real-time PCR (qPCR) based analysis is
described and compared to sequence specific primer PCR with capillary electrophoresis
(SSP PCR CE) on 149 patient-derived samples, using sequence specific oligonucleotide
hybridization combined with high resolution SSP PCR as gold standard. In addition to these
PCR based methods, a complementary approach was developed using flow cytometry with
an HLA-B17 specific monoclonal antibody as a pre-screening assay to diminish the number
of samples for genetic testing. All three assays had a maximum sensitivity of >99. However,
differences in specificity were recorded, i.e. 84.3%, 97.2% and >99% for flow cytometry,
qPCR and SSP PCR CE respectively. Our data indicate that the most specific and sensitive
of the compared methods is the SSP PCR CE. Flow cytometry pre-screening can substan-
tially decrease the number of genetic tests for HLA-B*57:01 typing in a clinical setting.
Introduction
Abacavir (ABC) is a nucleoside reverse transcriptase inhibitor that is used as a part of combina-
tion antiretroviral therapy in HIV-1-infected patients. In 5–8% of treated patients, ABC can in-
duce an immune mediated hypersensitive response that correlates with the presence of the
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HLA-B57:01 allele [1–3]. Consequently, current guidelines recommend screening for the pres-
ence of theHLA-B57:01 allele in all HIV infected patients before ABC initiation [3].
The ABC induced hypersensitivity syndrome is accompanied by mild to moderate rash, hy-
potension, fever and gastrointestinal and respiratory symptoms [2]. Symptoms disappear
shortly after treatment abrogation, but restart of treatment may lead to anaphylactic shock and
possible death [4–6]. The strong association of the hypersensitivity response with the presence
of the major histocompatibility complex (MHC) class I alleleHLA-B57:01 was confirmed in
the PREDICT-1 study (Clinical-Trials.gov ID: NCT00340080) [7–9]. Subsequently, the Ameri-
can case control study (SHAPE) on Caucasian and African patients confirmed a 100% correla-
tion between HLA-B57:01 and a positive skin patch test combined with a hypersensitive
response to ABC (Clinical-Trials.gov ID: NCT00373945) [10]. Together, these data clearly in-
dicate the importance ofHLA-B57:01 testing, which is now recommended before treatment
initiation with ABC [3].
Numerous genotypic tests exist for HLA-B57:01 screening. The gold standard method,
being sequence based typing of theHLA-B allele is laborious and expensive [11,12]. Conse-
quently, alternative tests have been developed to increase turn-around time and decrease assay
costs, while minimizing a decrease in specificity and sensitivity. A frequently used method is
based on hybridization of PCR products with sequence specific oligonucleotides (SSO), fol-
lowed by sequence specific primer (SSP)-PCR high resolution testing to assess whether the
HLA-B57 allele is present [13]. Currently, the most commonly used methods are based on
SSP PCR [14]. This method has been further optimized by subsequent capillary electrophore-
sis, enhancing the sensitivity of the assay [15]. More recently, new assays were developed for
HLA-B57:01 typing on a qPCR platform [11,16,17]. This enables detection of primer specifici-
ty through differentiating Cq values by SYBR Green quantitative (q)PCR [16], or analysis of al-
lele specific PCR by high resolution melting [17]. Implementation of these assays on a qPCR
platform significantly decreases the processing and reaction time as well as reagent costs [11].
A recent study on a 6 year long external quality assessment scheme ofHLA-B57:01 typing
in 47 laboratories from 12 different countries showed that routine clinical HLA-B57:01 typing
using various genotypic tests resulted in a single false negative HLA-B57:01 report from 1283
reports, indicating that current HLA typing is excellent [18]. However, innovations in HLA
typing strategies may still help laboratories decrease costs as well as turnaround time and may
facilitate in-house assay development.
Apart from the PCR based methods, flow cytometry with specific monoclonal antibodies
can also be used in HLA-B57:01 screening. Although no specific antibodies for HLA-B57:01
have been described; an antibody was recently developed that specifically binds to HLA-B57
and HLA-B58 [19]. Since only 10–5% of patients will test positive with this monoclonal anti-
body, the majority of patients will not require additional genotypicHLA-B57:01 testing. This
strategy can substantially reduce costs, and decrease time to result in the majority of patients
not requiring additional testing and sampling [20].
The present study was set up to compare different non-commercial HLA-B57:01 typing
tests in a routine clinical setting. In the present study, two PCR based tests for genotypic
HLA-B57:01 typing were evaluated. In addition, the complementary approach using flow cy-
tometry to precede genotypic testing was investigated. The sensitivity, specificity and positive
and negative predictive value were evaluated for their clinical utility.
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Materials and Methods
Study design and patient samples
The present study was divided in two consecutive sub-studies (Table 1). In the first retrospec-
tive study, 41 samples were procured from patients with a known HLA-B57:01 positive status,
as assessed by a previously validated SSO methodology (LIFECODES HLA-B SSO Typing Kit;
Immucor Transplant Diagnostics) which is routinely used by the Laboratory for Histocompati-
bility Immunogenetics of the Belgian Red Cross. Subsequently, prospective samples from 108
patients with unknownHLA-B57:01 type were collected and tested using flow cytometry, ge-
netic testing (qPCR and PCR SSP with capillary electrophoresis) and SSO as gold standard.
Blood was collected in 9 ml EDTA tubes by venipuncture. For PCR, peripheral blood mononu-
clear cells were isolated using density gradient centrifugation with Lymphoprep (Axis Shield).
Subsequently, cells were aliquoted in 1.6 ml tubes and stored as dry pellets in -80°C for qPCR
until DNA isolation, performed with the GenElute blood genomic DNA kit (Sigma-Aldrich).
Flow cytometry was performed on fresh blood. Fresh blood was available from all 108 patients
of the blinded study, but only from 23 of the 41 patients with knownHLA-B57:01 positive sta-
tus. The study was approved by the ethical committee of Ghent University Hospital (Belgian
reference number: B670201215101), this included a written consent form that was signed by
the participants.
Standard HLA-B*57:01 typing based on SSO and PCR SSPmethods
Standard HLA-B57:01 testing was performed by a complementary SSO and high resolution
SSP PCR method in a European Federation of Immunogenetics accredited Laboratory.
SSO was performed using the LIFECODES HLA-B SSO Typing Kit (Immucor Transplant
Diagnostics) using the manufacturer’s recommended protocols to define the presence of the
HLA-B57. If theHLA-B57 allele was present, the subtyping ofHLA-B57 was performed with
PCR-SSP.
PCR-SSP was performed using a high resolution PCR-SSP method (Olerup SSP) using the
manufacturer’s recommended protocols to discriminate between the different HLA-B57 sub-
types and to identify HLA-B57:01. After validation of the SSO method for the correct identifi-
cation of the HLA-B57:01 subtype (S1 Table) the 2nd step with high resolution PCR-SSP
confirmation was only performed on the HLA-B57 positive samples if the B57 subtype was
doubtful because of inconclusive oligonucleotide hybridization results.
Table 1. Overview of the substudies with patient numbers.
Flow cytometry qPCR SSP PCR CE SSO + PCR
Retrospective study
HLA-B*57:01 + n = 23 n = 41 n = 30 n = 41
(n = 41)
Prospective study
Blinded sampling n = 108 n = 108 n = 96 n = 108
(n = 108)
Representation of the substudies with the amount of samples tested per assay.
doi:10.1371/journal.pone.0123525.t001
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HLA-B*57:01 typing by Flow cytometry
Flow cytometry was performed on a FACSCanto II instrument (BD Biosciences). 50 μL of
blood was incubated with monoclonal HLA-B17 antibodies (mAb 3E12, kindly provided by
BD Biosciences) labelled with phycoerythrin and CD45 labelled with FITC as previously de-
scribed [19]. This antibody recognizes both HLA-B57 and HLA-B58 allotypes [19]. After 20
minutes incubation at room temperature erythrocytes were lysed with FACS lysis buffer and
washed twice. Then samples were resuspended in 500 μL phosphate buffered saline with albu-
min for analysis. At least 20.000 events were acquired for analysis. Lymphocytes were gated
based upon scatter and CD45 bright expression, and mean fluorescence intensity (MFI) for
HLA-B17 expression was measured.
HLA-B*57:01 typing by qPCR
The qPCR was based on the protocol described by Dello-Russo et al., that was adapted to avoid
the necessity of the initialHLA-B PCR [16]. This assay targets the exon 2 (Primers 193F, 319R
and HLA 57:01 exon 2 probe; S2 Table) and exon 3 (Primers 345F, 419R and HLAB57:01 exon
3 probe; S2 Table) region of theHLA-B57:01 allele. Primers were modified to increase specific-
ity (S2 Table). An extra base was inserted at the 5’ end of primer 193F (exon 2). Three bases
were removed from the 3’ end to position the primer in a more variable region of the HLA-B
sequence. In the 345F (exon 3) primer sequence, a T to C mismatch was artificially introduced
at the third position from the 3’ side. This mismatch has a limited impact on HLA-B57:01 am-
plification, but amplification is substantially impaired with non-HLA-B57:01 amplicons that
already harbor mismatches in the 3’ end region of the primer. In addition to these modifica-
tions, hydrolysis probes were used to increase specificity. These probes contain a 5’ FAM fluor-
ophore, a 3’ black hole quencher combined with an internal ZEN quencher (Integrated DNA
Technologies).
QPCR was performed on a LightCycler 480 system (Roche Applied Sciences) using the
LightCycler 480 Probes master mix (Roche Life Sciences). Each reaction was performed in du-
plicate in 5 μl reaction mix containing 1 μl (50–150 ng) of DNA isolate, 500 nM forward and
reverse primers and 10 nM of the hydrolysis probe. Cycling conditions consisted of an initial
denaturation of 5 min at 95 °C, then 40 cycles of a denaturation step at 95°C for 15 sec, and an
annealing/elongation step at 61°C. After cycling, quantification cycles (Cq) of each reaction
were obtained using the second derivative method within the Lightcycler 480 software (Roche
Life Sciences, version: SW 1.5).
Raw Cq values that differed by more than 8 cycles between one of the three reactions, i.e.
exon 1, exon 2 and RPP30 (primers RnasePf, RnasePR, RnaseP probe; S2 Table) were consid-
ered asHLA-B57:01 negative. Samples with smaller differences in Cq values were labeled posi-
tive for HLA-B57:01.
This modified qPCR method was compared to the assay originally described by Dello Russo
et al., inHLA-B57:01 positive patients [16]. For this assay a first PCR was performed to ampli-
fy a 922 bp fragment of the HLA-B allele using primer pair 5BIn1-57 and 5BIn3-37 (S2 Table).
PCR reactions were performed in 20 μl containing 2 μl of 10x PCR buffer (Life Technologies),
120 μM dNTPs, 2 mMMgCL2, 0.4 U Platinum Taq polymerase (Life Technologies), 300 nM
primers and isolated DNA at a final concentration of 1 ng/μl. PCR cycling consisted of a first
polymerase activation step at 95°C for 10 min, followed by 35 times denaturation at 95°C for
20 seconds and an annealing/extension step at 68°C for 1 min in an Applied Biosystems 2720
thermal cycler (Life Technologies). The PCR product was run on the LabChip GX system
(PerkinElmer) for microfluidic electrophoresis to assess whether the HLA-B amplicon was
properly amplified. Subsequently, qPCR was performed using the previously described primers
HLA-B*57:01 Typing to Assess Abacavir Hypersensitivity
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(S2 Table) [16]. PCR was performed in 5 μl using the 5X LightCycler 480 Probes mastermix
(Roche Life Sciences), with 0.25 μl of 20x LightCycler 480 ResoLight Dye (Roche Life Sciences),
500 nM of the primers and the product of the first PCR in a 1:10, 1:100 and 1:1000 dilution.
HLA-B*57:01 typing by Sequence specific PCR with capillary
electrophoresis (SSP PCR CE)
SSP PCR CE was performed as previously described using sequence specific primers (S2 Table)
[14,15]. The PCR reaction was performed in a total volume of 20 μl and consisting of 3–10 ng
input DNA, 1.25 μM primer 1F, 0.5 μM primers 2R, 3R and 4R and 0.25 μM primers HGH-F
and HGH-R (S2 Table), KAPA PCR buffer to a final concentration of 1s, 1.5 mMMgCl2, 0,025
U KAPA Taq Hot Start polymerase (KAPA Biosystems) and 0.12 mM dNTPs (Life Technolo-
gies). Cycling conditions included an incubation step for 3 min at 95°C followed by 30 cycles of
1 min at 95°C, 1 min at 63°C and 1 min at 72°C and a final incubation of 10 min at 72°C in an
Applied Biosystems 2720 thermal cycler (Life Technologies).
The PCR products were run on an Applied Biosystems 3130xL automated capillary se-
quencer (Life Technologies) with GeneScan 500 ROX dye size standard (Life Technologies)
and formamide for fluorescent readout of PCR fragments. Data analysis was performed using
the GeneMapper software (Life Technologies, S1 Fig).
Statistical analysis
Standard non parametric statistical analysis was performed using the wilcox.test function in
the R based MASS package (version 7.3–35).
Results
Retrospective analysis of samples with known HLA-B*57 status
(Table 2)
Because of the low frequency of the HLA-B57 allele in the general population, an initial retro-
spective study on samples with known HLA-B57 status was performed to allow a more accu-
rate estimation of the sensitivity of the assays.
Flow cytometry screening with the monoclonal HLA-B17 antibody using an original cut-off
at an MFI of 500 revealed a bright expression with an average MFI of 1.14x104 (SD = 4.35x103)
in all 23 retrospectively collected samples known to be positive for HLA-B57:01 (S3 Table), in-
dicating a>99% sensitivity of the flow cytometry screening (Table 2).
The qPCR method was positive for all 41HLA-B57:01 confirmed samples indicating a
>99% sensitivity of the qPCR based screening (Table 2). Average Cq differences in positive
Table 2. Characteristics of the testedmethods on the retrospective samples.
Flow cytometry qPCR SSP PCR CE
SSO + SSP PCR N HLA-B17 non HLA-B17 NA HLA-B*57:01 non-HLA-B*57:01 NA HLA-B*57:01 non-HLA-B*57:01
HLA-B*57:01 41 23 0 18 41 0 0 32 0 9
non-HLA-B*57:01 0 0 0 0 0 0 0 0
total 41 23 18 41 0 32 9
Sensitivity (%) >99 >99 >99
Characteristics of the three tested HLA-typing methods on the retrospective samples compared to the SSO and high resolution SSP PCR as gold
standard. (NA: Not Available).
doi:10.1371/journal.pone.0123525.t002
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samples between exon 2 and RPP30 PCRs was: 1.49 (SD = 0.713); between exon 3 and RPP30
PCRs was: 2.12 (SD = 0.87); and between exon 2 and exon 3 PCRs was: 0.71 (SD = 0.53).
SSP PCR CE was performed on 30 confirmed HLA-B57:01 positive samples. All samples
were correctly typed asHLA-B57 positive indicating a>99% sensitivity for the SSP PCR CE
method (Table 2).
Prospective analysis of samples with unknown HLA-B*57 status
(Table 3)
Flow Cytometry. Flow cytometry screening was performed on 108 prospectively collected
samples with unknownHLA-B57:01 status. This resulted in positive flow cytometry results for
17 samples (16%) of which only 2 patients were determined asHLA-B57:01 positive by SSO
(S4 Table). Of the 91 samples that were negative by flow cytometry, all samples were confirmed
negative by SSO. Within the 17 HLA-B17 positive samples, a comparison of the MFI of all
HLA-B57:01 positive samples versus HLA-B57:01 negative revealed that the latter had a sig-
nificantly lower MFI (p<0.0001 by Wilcoxon rank sum test) (S2 Fig). Assessment of the HLA
alleles that resulted in positive flow cytometry signals with the HLA-B17 antibody was subse-
quently performed by high resolution SSP PCR (Table 3 and S4 Table). This revealed that only
3 samples with theHLA-B57:03 allotype and 2 samples with the HLA-B58 allotype resulted
in fluorescent signals that were indiscernible from the fluorescent signals of HLA-B57:01 posi-
tive samples (S4 Table). Based on this data, the samples were re-assessed using a less stringent
cut-off at an MFI of 5000.
With the original cut-off at an MFI of 500, flow cytometry reached a sensitivity of>99%, a
specificity of 85.8%, a positive predictive value (PPV) of 11.8% and a negative predictive value
(NPV) of>99%. A re-analysis of the samples using the new, less stringent cut-off at an MFI of
5000 increased the PPV of 11.8% (using the initial cut-off at an MFI of 500) to 28.6% and
maintained the NPV at>99%.
qPCR. QPCR was performed on 108 prospectively collected samples. Analysis of the sam-
ples with unknownHLA-B57:01 status revealed that the twoHLA-B57:01 positive samples
were detected by qPCR. In addition to these, three false positive samples were detected by
qPCR compared to SSO. High resolution PCR SSP revealed that these samples all contained
Table 3. Characteristics of the testedmethods on the prospective samples.
Flow cytometry qPCR SSP PCR CE
SSO + SSP PCR N HLA-B17 non HLA-B17 NA HLA-B*57:01 non HLA-B*57:01 NA HLA-B*57:01 non HLA-B*57:01 NA
HLA-B*57:01 2 2 0 2 0 2 0 0
non HLA-B*57:01 106 15 91 3 103 0 92 14
total 108 17 91 0 5 103 2 92 14
PPV 11.8 40.0 100.0
NPV 100.0 100.0 100.0
Sensitivity (%) 100.0 100.0 100.0
Speciﬁcity (%) 85.8 97.2 100.0
TAT same day 1 day 1–2 days
Characteristics of the three tested HLA-typing methods compared to the SSO and high resolution SSP PCR as gold standard. The data from the ﬂow
cytometry study is based on the most stringent cut-off at an MFI of 500. (NA: Not Available; PPV: Positive Predictive Value; NPV: Negative Predictive
Value; TAT: Turn Around Time).
doi:10.1371/journal.pone.0123525.t003
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theHLA-B57:03 allele. These results indicate a sensitivity of>99% and specificity of 97.2%, a
PPV of 40% and an NPV of 100% (Table 3).
Sequence specific PCR with capillary electrophoresis (SSP PCR CE). SSP PCR CE was
performed on 96 of the 108 unknown samples from the blinded study. This method gave posi-
tive results for all confirmed positive samples.
From the unknown samples, the twoHLA-B57:01 were detected as HLA-B57:01 positive
and theHLA-B57:03 samples were assessed asHLA-B57 positive but different to
HLA-B57:01. These results indicate that both the assay sensitivity and specificity had a value
of>99% in the currently investigated samples (Table 3).
Discussion
The present paper describes the comparison of three different methods forHLA-B57:01 typing
that are suitable for use in a routine clinical laboratory, either as stand-alone tests or in a step-
wise protocol. The current data indicate that all tested assays had a maximal sensitivity, as no
patients were falsely allocated asHLA-B57:01 negative.
The high sensitivity of the flow cytometry assay with the HLA-B-17 monoclonal antibody at
detecting HLA-B57:01 positive samples renders this method a preferred assay for upfront
screening. However, the relatively low specificity of flow cytometry compared to genetic tests
makes it unsuitable as a stand-alone tool. Using flow cytometry 14% of patients will test false
positive for HLA-B57:01 as measured in the present cohort. Implementation of multiple
monoclonal HLA-B57:01 antibodies may increase the specificity of a flow cytometry test [21].
However, genetic screening remains necessary for samples with positive results using the
HLA-B17 antibodies. It should be noted that the limited turn-around time of the flow cytome-
try allows fast decision making. Additionally, flow cytometry may have a high value in resource
limited settings where flow cytometry is often more accessible and more affordable compared
to genetic screening tools [22].
The flow cytometry analysis of samples with unknown HLA type indicated that the
HLA-B17 antibody detects other alleles than previously reported [19,20]. There was a lower
fluorescence in many of these false positive samples compared to the true HLA-B57:01 posi-
tive samples (S2 Fig), but a stringent cut-off has to be applied to avoid the majority of false neg-
atives. In the present cohort, a possible cut-off set at an MFI of 5000 increased the PPV of
11.8% (with the original cut-off at an MFI of 500) to 28.6% while the NPV at>99% was
maintained.
The qPCR based screening allows an expedited screening of theHLA-B57:01 type com-
pared to the currently described qPCR assays. Contrarily to the assay described by Dello-Russo
et al, the present assay is not performed as a nested PCR [16]. Preliminary data with the nested
PCR design, indicated that the first PCR of the nested PCR protocol did not always result in
amplification of theHLA-B amplicon. The amplification efficiency of the first PCR is crucial as
a suboptimal PCR may render a positive sample false negative. Consequently, the direct qPCR
strategy with hydrolysis probes was preferred. An additional advantage of the direct PCR con-
sists of the internal reference gene (here RPP30) used to normalize for variations in the sample
input, and to assess sample quality, further enhancing the flexibility of the assay.
Despite the advantages of the qPCR assay, HLA-B57:03 alleles were indiscernible from
HLA-B57:01 positive samples (data not shown). This contrasts to the results observed earlier
using the nested PCR approach [16]. However, also with the nested set-up we were unable to
observe a difference between the B57:03 and B57:01 subtypes. This finding indicates that the
qPCR methodology has a lower specificity as previously reported, making it suboptimal com-
pared to the SSP PCR with capillary electrophoresis. Consequently, the latter method should
HLA-B*57:01 Typing to Assess Abacavir Hypersensitivity
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be considered as a preferred method over the qPCR if capillary electrophoresis equipment
is available.
In conclusion, our data indicate that the most specific and sensitive of the compared tests
among those compared are the SSP PCR CE and the SSO. A combined approach with pre-
screening by flow cytometry forms a valid alternative to limit the amount of genotypic testing.
Supporting Information
S1 Fig. Flow cytometry based HLA-B17 typing. A & B: Flow cytometry fluorescence intensity
histograms of lymphocytes stained with the HLA-B17 antibody for anHLA-B57:01 positive
(A) and negative sample (B), showing a clear discrimination of HLA-B17 positive versus nega-
tive samples. C: Scatterplot of Mean Fluorescence Intensities (MFI) of HLA-B17 positive sam-
ples that were either HLA-B57:01 positive or negative based on SSO and SSP PCR as the gold
standard. Apart from theHLA-B58 (cubes) and HLA-B57:03 (diamonds), all other non-
HLA-B57:01 alleles (triangles) had a markedly lower MFI with the HLA-B17 antibody com-
pared to the HLA-B57:01 positive samples (dots).
(TIF)
S2 Fig. SSP PCR CE basedHLA-B57:01 typing. Electropherograms of the SSP PCR CE assay
with specific bin for HLA-B57:01 (left),HLA-B57 (middle) and for the positive control
(right). Sample A isHLA-B57:01 positive, as it results in a positive peak in each bin. Sample B
contains theHLA-B57:03 allele (as assessed by high resolution PCR SSP) and has a positive
signal in the middle bin, but not in the left bin. Sample C isHLA-B57 negative, as it has no
positive peak in the left and middle bin, but a clearly positive peak in the right bin, showing
that the reaction was succesful, but that theHLA-B57:01 allele was not present.
(TIF)
S1 Table. Validation of the PCR SSO. Overview of the validation data of PCR-SSO correlated
to the PCR-SSP high resolution results as previously performed with a set of confirmed
HLA-B57:01 positive samples. Oligonucleotides in the SSO typing kit that react with
HLA-B57:01 toHLA-B57:04 (n = 14) are indicated in blue, oligonucleotides that define the
differences betweenHLA-B57:01 toHLA-B57:04 (n = 8) are indicated in red and oligonucleo-
tides that react with specificities on other HLA alleles are indicated in black and are not rele-
vant for this study.
(XLSX)
S2 Table. Primers and probes. Primers and probes used in this study, including the specific
annealing temperatures (Ta) for the qPCR.
(XLSX)
S3 Table. Individual test results of the retrospective study. Test results of each patient for the
retrospective study, including the gold standard method (SSO combined with high resolution
SSP PCR), qPCR, SSP PCR CE and flow cytometry.
(XLSX)
S4 Table. Test results of the prospective study. Test results of each patient in the prospective
study, including the gold standard method (SSO combined with High Resolution PCR), qPCR,
SSP PCR CE and flow cytometry.
(XLSX)
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